India records 93,249 new COVID-19 cases, in highest single-day rise since 19 September
The toll climbed to 1,64,623 on Sunday with 513 new fatalities, the health ministry's data updated at 8 am showed
New Delhi: India on Sunday recorded 93,249 new coronavirus infections, the highest single-day rise so far this year, which took the total COVID-19 cases to 1,24,85,509, according to Union health ministry data.
This is the biggest daily rise in cases since 19 September, when 93,337 fresh infections were recorded.
The death toll climbed to 1,64,623 on Sunday with 513 new fatalities, the ministry data updated at 8 am showed.
Registering a steady increase for the 25th day in row, the active cases surged to 6,91,597, accounting for 5.54 percent of the total infections. The recovery rate further dropped to 93.14 percent, the data stated.
The active caseload was at its lowest at 1,35,926 on 12 February, comprising 1.25 percent of the total infections.
The number of people who have recuperated from the disease increased to 1,16,29,289, while the case fatality rate stands at 1.32 percent, according to the data.
India's COVID-19 tally had crossed the 20-lakh mark on August 7, 30 lakh on August 23, 40 lakh on September 5 and 50 lakh on September 16. It went past 60 lakh on September 28, 70 lakh on October 11, 80 lakh on October 29, 90 lakh on November 20 and surpassed the one-crore mark on December 19.
According to the Indian Council of Medical Research, 24,81,25,908 samples had been tested up to 3 April with 11,66,716 being tested on Saturday.
COVID-19 vaccine hesitancy: Govt must take cue from global examples, roll out targeted information campaigns
Vaccine hesitancy has been compounded by the ongoing experience of surviving in the COVID-19 pandemic and the associated uncertainty
COVID-19 vaccination must focus on worst-hit districts; people must practice safety norms, say Gujarat health experts
India must record suspected COVID-19 cases in addition to confirmed ones to get a more accurate picture, said Gujarat-based healthcare experts Dileep Mavalankar and Sanket Mankad
The efficacy rate is based on a second interim analysis of phase 3 clinical data and Bharat Biotech said that the safety and efficacy results from the final analysis will be available in June